Salix sinks as audit admission hurts M&A potential
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals lost 38.3% of its recently rising value – chopping more than $3bn from its market cap – after the stock market closed on 6 November following the immediate resignation of the company's chief financial officer and Salix's admission that an audit of its inventory levels is ongoing.